Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Question for Whalewatcher
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(5)
•••
Comment by TheBearInTheWoodson Dec 31, 2021 1:12am
87 Views
Post# 34273059

RE:RE:RE:RE:RE:RE:RE:RE:RE:Question for Whalewatcher

RE:RE:RE:RE:RE:RE:RE:RE:RE:Question for Whalewatcher

Well put Whale, you can't fake it to the Nasdaq by putting lipstick on a pig with a 100-1 consolidation and think the market will reward you. 

No patents + No money = .04 share price just like Xrtx , only a licensed drug .... sound familiar? 


Whalewatcher1 wrote: You should check out the streetwise report on algernon today. Keep in mind that algernon pays for this report. Chris provides examples of Nasdaq up listing  in xortx and Diamedica, neither worked out for investors. Xortx just uplisted- was trading at $6 early October on CSE, raised $12m at $4 (typical discount) a share early October and now trades at below $2, but is Nasdaq listed. Nasdaq price was in line with CSE pricing before collapsing after listing on Nasdaq. Thoughts on this most recent example? Lots to look forward to . . . 

 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities